Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock (NCT07345559) | Clinical Trial Compass
RecruitingNot Applicable
Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock
France406 participantsStarted 2026-03-26
Plain-language summary
Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous pressure (CVP) can help assess effective perfusion pressure. This study investigates whether a personalized MAP target adjusted by CVP improves organ function and survival compared to standard MAP management.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged ≥18 years
* Cardiogenic shock state, according to the consensus definition,
* SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C
* Consent from the patient or close relative / trusted person or emergency inclusion procedure
* Benefiting fromciary of a social security scheme
Exclusion Criteria:
* Catecholamine infusion for more than 24 consecutive hours;
* CVP \< 5 mm Hg at inclusion;
* MAP \> 70 mmHg at inclusion;
* Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to the KDIGO CKD classification at inclusion;
* Chronic dialysis or presence of renal replacement therapy criteria at inclusion ;
* Recovered cardiopulmonary arrest within 7 days prior to inclusion;
* Patient already on mechanical circulatory support at inclusion before enrollment (patients who receive support after inclusion will not be excluded);
* Primary diagnosis of tamponade, pulmonary embolism, or septic shock;
* Hypersensitivity to norepinephrine tartrate or to any of the following excipients: sodium chloride, hydrochloric acid or sodium hydroxide water for injectable preparations;
* Absence of central venous access;
* Known pregnancy or current breastfeeding;
* Under legal guardianship, curatorship, or judicial protection.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The primary endpoint will be a composite of mortality, use of cardiac mechanical circulatory support, and severe renal failure.